PŘEHLEDOVÉ ČLÁNKY Pokroky v diagnostice a léčbě systémového lupus erytematodes | 383 / Vnitř Lék. 2025;71(6):377-383 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz 10. Italiani P, Manca M, Angelotti F, et al. IL-1 family cytokines and soluble receptors in systemic lupus erythematosus. Arthritis Res Ther. 2018;20:27. 11. Suh CH, Kim SS, Hong SJ, et al. Novel diagnostic biomarker of systemic lupus erythematosus – antichaperonin containing T-complex peptide 1 antibody. J Rheumatol. 2025;52(Suppl 1):99-100. 12. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83:15-29. 13. Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Kidney Int. 2024;105(1S):S1-S69. 14. Horák P. Principy léčby SLE dle aktualizovaných doporučení EULAR 2023 – komentář. Čes Revmatol. 2024;32(3):107-115. 15. www.sukl.cz. Available from: https://www.sukl.cz 16. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Care Res. 2009;61:1168-1178. 17. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918-3930. 18. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721-731. 19. Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two–week randomized, double-blind placebo-controlled study. Arthritis Rheumatol. 2017;69:1016-1027. 20. Zhang F, Bae SC, Bass D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018;77:355-363. 21. Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of Belimumab in lupus nephritis. N Engl J Med. 2020;383:1117-28. 22. Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis Rheumatol Hoboken NJ. https://doi.org/10.1002/ art. 41466. Epub ahead of print 4 August 2020. 23. Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in moderate-to-severe systemic lupus erythematosus: Anifrolumab in moderate-to-severe SLE. Arthritis Rheumatol. 2017;69:376-86. 24. Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1:e208-19. 25. Morand EF, Furie R, Tanaka Y, et al. Trial of Anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211-21. 26. Jayne D, Rovin B, Mysler F, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022;81:496-506. 27. Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately- -to -severely active systemic lupus erythematosus: the randomized, double -blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan;62(1):222-33. 28. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012 Apr;64(4):1215-26. doi: 10.1002/art.34359. Epub 2012 Jan 9. PMID: 22231479. 29. Gomez Mendez LM, Cascino MD, Garg J, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13:1502-9. 30. Kalunian KC, Merrill JT, Maciuca R, et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75:196-202. 31. Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:1909-1916. 32. Furie R, Dooley MA, Wofsy D, et al. A phase III randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept or placebo on standard of care in patients with active class III or IV lupus nephritis. Ann Rheum Dis. 2018;77:176-177. 33. Furie RA, Leon G, Thomas M, et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015;74:1667-1675. 34. Merrill JT, Shanahan WR, Scheinberg M, et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018;77:883-889. 35. Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:323-331. 36. Merrill JT, van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:332-340. 37. Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74:2006-2015. 38. Wu D, Li J, Xu D, et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2 b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2024;83:475-487. 39. Furie R, Aroca G, Alvarez A, et al. A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obinutuzumab or placebo in combination with mycophenolate mofetil in patients with active class III or IV lupus nephritis [abstract]. Arthritis Rheumatol. 2019;71(Suppl 10). 40. Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65:2368-2379. 41. van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018;392:1330-1339. 42. Furie RA, Bruce IN, Dörner T, et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology. 2021;60:5397-5407. 43. Clowse M, Isenberg D, Merrill J, et al. Dapirolizumab pegol demonstrated significant improvement in systemic lupus erythematosus disease activity: efficacy and safety results of a phase 3 trial [abstract]. Arthritis Rheumatol. 2024;76(Suppl 9). Available from: https://acrabstracts.org/abstract/dapirolizumab-pegol-demonstrated-significant-improvement-in-systemic-lupus-erythematosus-disease-activity-efficacy-and-safety-results-of-a- -phase-3-trial/ [cited 2025 Jul 12]. 44. Furie RA, van Vollenhoven RF, Kalunian K, et al. Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus. N Engl J Med. 2022;387:894-904. 45. Merrill JT, Tanaka Y, D‘Cruz D, et al. Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: a phase 2 randomized controlled trial. Arthritis Rheumatol. 2024;76:1518-1529. 46. Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2023;75:242-252. 47. Chan J, Walters GD, Puri P, et al. Safety and efficacy of biological agents in the treatment of systemic lupus erythematosus (SLE). BMC Rheumatol. 2023;7:37. 48. Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023;402:2034-2044. 49. Schett G, Müller F, Taubmann J, et al. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol. 2024;20:531-544. 50. Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28:2124-2132. 51. Hagen M, Bucci L, Böltz S, et al. BCMA-targeted T-cell-engager therapy for autoimmune disease. N Engl J Med. 2024;391:867-869. 52. Alexander T, Krönke J, Cheng Q, et al. Teclistamab-induced remission in refractory systemic lupus erythematosus. N Engl J Med. 2024;391:864-866. 53. Bucci L, Hagen M, Rothe T, et al. Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat Med. 2024;30:1593-1601. 54. Parodis I, Girard-Guyonvarc‘h C, Arnaud L, et al. EULAR recommendations for the non- -pharmacological management of systemic lupus erythematosus and systemic sclerosis. Ann Rheum Dis. 2024;83(6):720-729. 55. Saegusa K, Tsuchida Y, Komai T, et al. Advances in targeted therapy for systemic lupus erythematosus: current treatments and novel approaches. Int J Mol Sci. 2025;26(3):929.
RkJQdWJsaXNoZXIy NDA4Mjc=